The Arizona ADC, which includes the state-supported Arizona Alzheimer's Research Center (ARC) and the NIH-sponsored Arizona Alzheimer's Disease Core Center (ADCC), has become a national model of multi-institutional, multi-disciplinary collaboration in biomedical research. The Arizona ARC involves Arizona's nine leading biomedical research institutions and capitalizes on the state's complementary resources in brain imaging, computer science, the basic and behavioral neurosciences, and clinical and neuropathological research. The ADC supports approximately 40 research projects each year, and is designed to help in the understanding, early detection, tracking, treatment and prevention of Alzheimer's disease. The Arizona ADCC is one of 29 national Alzheimer's disease Centers - the National Institute on Aging's most prestigious award for productive Alzheimer's disease research programs - and the nation's first statewide Alzheimer's Disease Center consortium. The ADCC provides administrative, clinical, neuropathological, and educational cores which support a range of scientific activities. Distinguishing features of the Arizona ADC include the use of brain imaging techniques for the early detection and tracking of Alzheimer's disease in people at risk for the disorder, the identification of potentially important risk factors and molecular events (e.g., those related to inflammation and cholesterol), and innovative outreach programs for Arizona's underserved Hispanic and Native American communities.

Dr. Reiman's brain imaging research program capitalizes on PET and MRI resources at BGSMC, talented collaborators and imaging resources from several institutions. The program works to develop innovative imaging methods to investigate regions of the brain that work in concert to orchestrate normal behaviors (e.g., emotion, memory, and appetite) and those that conspire to produce behavioral disorders (e.g., Alzheimer's disease, anxiety disorders, and central pain). He and his colleagues have been tracking the brain changes that precede the onset of memory and thinking problems in carriers of a common Alzheimer's disease susceptibility gene and have developed an efficient brain imaging strategy to test the efficacy of drugs to treat and prevent this disorder.

One goal of the TGen Neurogenomics program is to characterize genes that are differentially expressed in relationship to each of the histopathological and metabolic features of Alzheimer's Dementia (AD), providing new targets for the discovery of drugs to treat and prevent this increasingly common, devastating disorder. Dr. Reiman aims to coordinate and capitalize on the rich resources available throughout the state to bring real results to patients suffering from psychiatric, neurologic, and neurodevelopmental disorders.

Dr. Reiman obtained his undergraduate degrees in zoology and philosophy from Duke University. His senior year, Dr. Reiman received the Angier B. Duke In-Class Memorial Scholarship to study abroad at Oxford University, Oxford, England. He then returned to Duke University where he attended medical school. His residency in psychiatry was completed at Duke, and then at Washington University School of Medicine. He remained at Washington University as a fellow at the McDonnell Center for Higher Brain Function and eventually an Assistant Professor of Psychiatry before moving on to the University of Arizona as Associate Professor of Psychiatry at College of Medicine. He is currently the Deputy Editor for the Journal of Clinical Psychiatry, Scientific Director at Banner Good Samaritan Medical Center, Phoenix, Arizona, and a member of the Clinical Neuroscience and Biological Psychopathology Review Committee. In addition, Dr. Reiman is the Associate Head for Research and Development for the Psychiatry Department and Professor of Psychiatry at the University of Arizona, Scientific Director at the Arizona Alzheimer’s Research Center, and Director of the Arizona Alzheimer’s Disease Core Center. In 2003, he assumed the position of Clinical Director of the Neurogenomics Division at TGen.